Hercules, Calif. — August 30, 2018 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.
CHT Ceramic Hydroxyapatite XT (CHT XT) Mixed-Mode Media
CHT Ceramic Hydroxyapatite XT (CHT XT) Mixed-Mode Media was formulated in response to customers' need for a more robust and stable resin that can maintain the superior performance of CHT resins. CHT XT offers high resolution and efficient single-step clearance of aggregates and other impurities such as HCP, dsDNA, endotoxins, and leached Protein A. It can be used in applications such as purification of enzymes, monoclonal and polyclonal antibodies of various classes, antibody fragments, and bispecific antibodies; efficient isolation and purification of viruses and virus-like particles (VLPs); and, separation of supercoiled DNA from linear duplexes as well as single-stranded from double-stranded DNA.
Key benefits of CHT XT Media
- Unique selectivity — binds by cation exchange and affinity interactions, unlike any unimodal resin
- Cost efficiency — reusability improves economy of the process purification workflow
- Time efficiency — can be used for single-step clearance of aggregates and other impurities
- Broad chemical compatibility — is compatible with a wide range of chemicals
To learn more about CHT Ceramic Hydroxyapatite XT (CHT XT) Mixed-Mode Media, please visit bio-rad.com/CHT-XT.
Nuvia HP-Q Anion Exchange Resin
Nuvia HP-Q Anion Exchange Resin was introduced to fill customers’ need for a high-performance resin compatible with high-throughput (HTP) large biomolecule purification. It can be used for downstream purification of large molecules such as high molecular weight (HMW) plasma proteins IgA and IgM, viruses, VLPs, and PEGylated proteins.
Key benefits of Nuvia HP-Q Resin
- Time efficiency and HTP compatibility — high flow rate compatibility (300 cm/hr) and fast mass transfer kinetics ensure purifications can be performed in less time
- Cost efficiency — lifetime of more than 100 cycles without loss of dynamic binding capacity (DBC) allows repeated use
- Mechanical stability — resin column holds up under the flow rates required for manufacturing-scale purification
- High productivity — excellent DBC (>50 mg/ml) with optimized pore structure, spacer length, and ligand density improves productivity
To learn more about Nuvia HP-Q Anion Exchange Resin, please visit bio-rad.com/Nuvia HP-Q.
Both media will be on display at BioProcess International Conference & Exhibition in Boston, September 5–7. At the event Bio-Rad will also host daily Design of Experiment (DoE) Workshops in Booth 1617 to discuss best strategies for screening new resins and tools to facilitate experimental design. Highlights of DoE workshop include:
- Introduction of new chromatography resins and best DoE practices
- Discussion of new ChromLab 6.0 Software features
- Exploration of how multivariable scouting with the NGC Chromatography System aids in DoE
- Visualization of stain-free gels and western blots with the ChemiDoc MP Imaging System
- Detection of impurities before and after purification with the Droplet Digital PCR System
To attend a DoE Booth Workshop, please visit bio-rad.com/BPIworkshop.
Bio-Rad and CHT are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has been at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and industry customers through its global network of operations. The company employs approximately 7,600 people worldwide and had revenues exceeding $2 billion in 2012. Visit us at www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "can," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.